View all opportunities

Use the Filter Opportunities panel on the right to filter these results.

Generic Multaq (dronedarone) Co-Development Opportunity [Opportunity for a buyer]
29 August 2014
Multaq is the first anti-arrhythmia drug approved since amiodarone was approved in 1985. We have developed a non-infringing generic formulation.
Generic to Bifril and Bifrizide from Menarini
Metamizole sodium oral solution 500mg/ml and tablets 500mg [Opportunity for a buyer]
06 August 2014
Generic to Novalgin from Sanofi.
Omega-3 90 ethyl esters capsules [Opportunity for a buyer]
04 August 2014
Generic to Omacor/Abbott. Omega-3 90 ethyl esters 1000mg soft gel capsules (460mg EPA/380mg DHA).
Solifenacin succinate tablets [Opportunity for a buyer]
04 August 2014
Generic to Vesicare/Astellas. Solifenacin succinate 5mg and 10mg film-coated tablets.
Risedronate sodium tablets [Opportunity for a buyer]
04 August 2014
Generic to Actonel/Sanofi. Risedronate sodium 35mg and 75mg film-coated tablets.
Seeking dossiers/products for MENA region [Opportunity for a seller]
31 July 2014
We are seeking dossiers for pharmaceutical products with zone IV a / b stability and bioequivalence studies meeting the requirements of the MENA region
Partners wanted for generic injectables [Opportunity for a buyer]
21 July 2014
Gland Pharma - a global generic injectable company based in India - is seeking out-licensing partners in the European Union.
Pregabalin capsules and oral solution [Opportunity for a buyer]
15 July 2014
Generic to Lyrica/Pfizer. Pregabalin 25mg/50mg/75mg/150mg/300mg hard gel capsules and 20mg/ml oral solution.
Cinacalcet 30mg, 60mg and 90mg film-coated tablets [Opportunity for a buyer]
03 July 2014
Generic to Mimpara®/ Amgen inc
Rasagiline 1mg tablets [Opportunity for a buyer]
03 July 2014
Generic to Azilect ® / Teva Lundbeck
Generic to Fosavance® / MSD Sharp & Dohme GmbH. Alendronate + Vit D3 70mg/2.800 I.E. and 70mg/5.600 I.E. film coated tablets
Valganciclovir 450mg film-coated tablets [Opportunity for a buyer]
03 July 2014
Generic to Valcyte® / Hoffmann La-Roche
Ready MA available in Turkey for sale [Opportunity for a buyer]
15 May 2014
Ready MAs available in Turkey for sale/out-license.
In-licensing of Anagrelide in EU [Opportunity for a seller]
09 May 2014
We are seeking to in-license Anagrelide for EU markets.
Bosentan 62.5mg and 125mg film-coated tablets [Opportunity for a buyer]
01 December 2013
Generic to Tracleer®/ Roche
Seeking dossiers/products for MENA region [Opportunity for a seller]
16 October 2013
Ready dossiers for pharma products with zone IV a / b stability and meeting requirements of the MENA region.
Dossiers required for EU, USA and MENA [Opportunity for a seller]
22 September 2013
We require dossiers for a broad range of medicines for the EU, USA and MENA on a non-exclusive basis.
Licensing of Oral Drug Delivery Products [Opportunity for a buyer]
19 September 2013
Athena have developed CTD dossiers on Oral Drug Delivery Products that we are looking to license out to partners who can receive products either in finished packs or bulk for local compression/encapsulation.
Ellis Pharma are the leading suppliers of global originator / innovator product to the pharmaceutical industry. Our strong manufacturer and supplier relationships allow us to access medicines on a global scale in order for you to be able to conduct the study you require.
Generic Invega Sustenna Injection Depot [Opportunity for a buyer]
31 August 2013
Updated on 29 August 2014
This is an extended release injection product that is being developed as an NDA in the USA and as an EU CTD MAA, as a low cost alternative to Invega Sustenna Injection Depot.
Clarithromycin XL [Opportunity for a buyer]
05 August 2013
Antibiotic.
Pioglitazone [Opportunity for a buyer]
05 August 2013
Diabetes.
Atorvastatin [Opportunity for a buyer]
05 August 2013
Cholesterol lowering.
Lanreotide LAR: Non-Infringing Generic of Somatuline Autogel Depot [Opportunity for a buyer]
05 August 2013
Updated on 29 August 2014
The product is a 30-day depot formulation being developed as an EU CTD MAA and as a USA NDA 505 (b)(2) that is non-infringing.
Risperidone Injectable Depot: A Generic to Risperdal Consta [Opportunity for a buyer]
31 July 2013
Updated on 29 August 2014
This is an extended release injection product that is being developed as an ANDA and as an EU CTD MAA.
Deferasirox Dispersable Tablets: for Oral Suspension: A Generic Product to Exjade [Opportunity for a buyer]
31 July 2013
Updated on 29 August 2014
The oral dispersible tablets are available in 125mg, 250mg and 500mg strengths.
Octreotide LAR: A Generic to Sandostatin LAR [Opportunity for a buyer]
15 July 2013
Updated on 28 August 2014
The product is a 30-day depot formulation being developed as an EU CTD MAA.
Fluticasone + Salmeterol DPI: Generic Product to Seretide DISKUS [Opportunity for a buyer]
15 July 2013
Updated on 28 August 2014
This product is identical in every respect to Seretide Diskus. MA was granted in one EU country in 2013 and is launched. It is still available for license in some EU countries, and for all countries outside of Europe except the USA.
Biosimilar Adalimumab mAb with Phase III pK/PD in Humans [Opportunity for a buyer]
15 July 2013
Updated on 28 August 2014
This product is highly similar to Humira and is fully documented, with stability according to EU requirements; with regulatory analytics according to the EU requirements; and, proof of comparability in a phase I human study. Phase III pK/PD comparative clinical studies in humans were completed in 2013.
Once Daily Extended Release Methylphenidate: Generic to Concerta [Opportunity for a buyer]
15 July 2013
Updated on 28 August 2014
This once-daily generic product treats attention deficit disorder (ADHD) and is available for license outside the USA including Europe. It is manufactured in USA FDA inspected facility and launched in the USA.
Biosimilar Bevacizumab mAb Product with Phase I pK/PD in Humans [Opportunity for a buyer]
15 July 2013
Updated on 28 August 2014
This product (100 and 400mg vials) is highly similar to Avastin and is fully documented, with comparability and stability according to EU requirements; with regulatory analytics according to EU requirements; and, proof of comparability in a phase I pK/PD comparative clinical study in humans.
Biosimilar Rituximab with Phase I and phase III pK/PD in Humans [Opportunity for a buyer]
15 July 2013
Updated on 29 August 2014
This product is highly similar to MabThera and is fully documented, with stability and comparability according to EU and USA requirements; and, proof of comparability with phase I and phase III pK/PD comparative clinical studies in humans.
Zonisamide capsules 25mg, 50mg, 100mg [Opportunity for a buyer]
03 July 2013
Anticonvulsant
Phenytoin sodium tablets 100mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Olmesartan FC tablets, 10mg, 20mg, 40mg [Opportunity for a buyer]
03 July 2013
Hypertension
Linezolid tablets 600mg [Opportunity for a buyer]
03 July 2013
Antibiotic
Ezetimibe tablets 10mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Calcipotriol ointment 0.05% w/w [Opportunity for a buyer]
03 July 2013
Psoriasis
Atovaquone suspension 750 mg/ml [Opportunity for a buyer]
03 July 2013
Anti-Malarial
Acamprosate DR Tablets 333mg [Opportunity for a buyer]
03 July 2013
Addiction
Zolmitriptan ODT Tablets 2.5mg, 5mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Zolmitriptan Tablets 2.5mg, 5mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Voriconazole Tablets 50mg, 200mg [Opportunity for a buyer]
03 July 2013
Antifungal
Trospium Tablets 15mg, 20mg, 30mg [Opportunity for a buyer]
03 July 2013
Antispasmodic
Topiramate Tablets, 25mg, 50mg, 100mg, 200mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Telmisartan HCTZ Tablets, 40/12.5mg, 80/12.5mg, 80/25mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Telmisartan Tablets, 20mg, 40mg, 80mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Rosuvastatin Tablets 5mg, 10mg, 20mg, 40mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Ropinirole Tablets 0.25mg, 0,5mg, 1mg, 2mg, 5mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Rizatriptan ODT Tablets 5mg, 10mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Rizatriptan Tablets 5mg, 10mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Riluzole Tablets 50mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Pramipexole Tablets 0.088mg, 0.18mg, 0.35mg, 0.7mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Phenytoin Sodium capsules 25mg, 50mg, 100mg, 300mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Perindopril/Indapamide Tablets 2/0.625mg, 4/1.25mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Perindopril Tablets: 2mg, 4mg, 8mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Olanzapine ODT Tablets 5mg, 10mg, 15mg, 20mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Nebivolol Tablets 5mg, 10mg [Opportunity for a buyer]
03 July 2013
Cardiovascular
Montelukast Film Coated Tablets 10mg [Opportunity for a buyer]
03 July 2013
Respiratory
Montelukast Chewable Tablets 4mg, 5mg [Opportunity for a buyer]
03 July 2013
Respiratory
Mometasone Cream 0.1% w/w [Opportunity for a buyer]
03 July 2013
Psoriasis
Mometasone Ointment 0.1% w/w [Opportunity for a buyer]
03 July 2013
Psoriasis
Levocetirizine Tablets 5mg [Opportunity for a buyer]
03 July 2013
Antihistamine
Imiquimod Cream 5% w/w [Opportunity for a buyer]
03 July 2013
Genital Warts
Gemcitabine Injection: 200mg, 1g [Opportunity for a buyer]
03 July 2013
Oncology
Escitalopram Tablets 5mg, 10mg, 15mg, 20mg [Opportunity for a buyer]
03 July 2013
Central Nervous System
Desloratadine Tablets 5mg [Opportunity for a buyer]
03 July 2013
Antihistamine
Atovaquone/Proguanil Tablets 250/100 mg [Opportunity for a buyer]
03 July 2013
Anti-Malarial
Vitamin D3 ATC A11CC05 [Opportunity for a buyer]
19 April 2013
Prevention and treatment of vitamin D deficiency in the elderly.
Omega 3 Acid Ethyl Esters 84% ATC C10AX06 [Opportunity for a buyer]
19 April 2013
Lipid reducers.
Nicorandil ATC C01DX16 [Opportunity for a buyer]
19 April 2013
Vasodilatory for angina treatment.
Imipenem Plus Cilastatin [Opportunity for a buyer]
19 April 2013
Antibiotic ATC J01DH51.
Aciclovir 5% Lipstick [Opportunity for a buyer]
19 April 2013
Lipstick 3g - 5% aciclovir.
Nicotine Chewing Gum [Opportunity for a buyer]
16 August 2012
Alkalon offers a range of finished product formulations and is seeking partnership opportunities worldwide. 2 and 4 mg available in several flavours. Our Nicotine Polacrilex Chewing Gum portfolio is based on a high quality dossier and has received MA's in several EU countries.

Filter Opportunities

Search for

Testimonials

Einar Geir Hreinsson, Vice-President Strategic Projects at Actavis, says:
"We used this channel to reach potential customers and it turned out to be considerably more effective than we had expected. It is invaluable to be able to introduce a new project like Opening Pharma in this way, through a single portal with connections in all directions. This will be our first choice the next time we want to give a new project a good promotion."

Rich DiCicco, Chief Executive Officer of Harvest Moon Pharma, comments:
"Harvest Moon Pharma has listed its complex generics and biosimilars on SourceGenerics for three years. We have received enquiries from 206 companies - including Pfizer, Sanofi, Teva, Stada, Ranbaxy and Sandoz - from 58 countries, and we are very pleased with the results. We intend to keep listing on SourceGenerics indefinitely."

Sanjiv Puri, Chief Executive Officer of Australia's Generic Partners, tells us:
"Within a week of posting our business opportunities on SourceGenerics we had received over 10 quality enquiries from leading generics companies throughout the world."

Why don't you post an opportunity or call us to see how we can help you find what you're looking for.